Cell Line Retrovirus Clonogenic Efficiency (Relative to C127 Cells) Inhibition of Clonogenicity (Relative to LXSN)
MCF7 (n=4) LXSN 2.0% N/A
ErbB4 1.6% 15 ± 2%
ErbB4 Q646C 0.04% 97 ± 1%
ErbB4 Q646C K751M 3.3% None
ErbB4 Q646C V673I 2.5% None
ErbB4 Q646C LL783/4AA 2.4% None
ErbB4 Q646C LL867/8AA 0.5% 70 ± 7%
ErbB4 Q646C L985A 2.9% None
ErbB4 Q646C D990A 1.2% 35 ± 13%

Table 1: The K751M, V673I, LL783/4AA, and L985A mutations markedly disrupt the tumor suppressor activity of the constitutively-active ErbB4 Q646C mutant in the MCF7 human breast tumor cell line.

Cell Line Retrovirus Clonogenic Efficiency (Relative to C127 Cells) Inhibition of Clonogenicity (Relative to LXSN)
Expt. 1 MCF10A (n=4) LXSN 9.8% N/A
ErbB4 10.0% None
ErbB4 Q646C 0.8% 91 ± 1%
ErbB4 Q646C K751M 8.5% None
ErbB4 Q646C V673I 8.5% None
Expt. 2MCF10A(n=3) LXSN 4.3% N/A
ErbB4 6.2% None
ErbB4 Q646C 0.5% 87 ± 2%
ErbB4 Q646C K751M 9.5% None
ErbB4 Q646C LL783/4AA 7.4% None
ErbB4 Q646C LL867/8AA 1.8% 58 ± 6%
Expt. 3MCF10A(n=3) LXSN 5.8% N/A
ErbB4 7.1% None
ErbB4 Q646C 0.6% 88 ± 3%
ErbB4 Q646C K751M 7.4% None
ErbB4 Q646C L985A 5.8% None
ErbB4 Q646C D990A 4.4% 28 ± 13%

Table 2: The K751M, V673I, LL783/4AA, and L985A mutations markedly disrupt the tumor suppressor activity of the constitutively-active ErbB4 Q646C mutant in the MCF10A human breast epithelial cell line.

Cell Line Retrovirus Clonogenic Efficiency (Relative to C127 Cells) Inhibition of Clonogenic Proliferation (Relative to ErbB4 Q646C K751M)
DU-145 (n=4) ErbB4 Q646C K751M 7.4% N/A
ErbB4 Q646C 0.3% 95 ± 2%
ErbB4 Q646C EGFP 6.0% 15 ± 9%
ErbB4 Q646C EGFP-TVV 1.2% 83 ± 4%
PC-3 (n=3) ErbB4 Q646C K751M 12.0% N/A
ErbB4 Q646C 1.4% 90 ± 3%
ErbB4 Q646C EGFP 10.9% 15 ± 8%
ErbB4 Q646C EGFP-TVV 1.1% 89 ± 3%

Table 3: Adding a carboxyl-terminal Enhanced Green Fluorescent Protein (EGFP) tag to the constitutively-active ErbB4 Q646C mutant disrupts its tumor suppressor activity, but this deficit is rescued by adding a carboxylterminal Thr-Val-Val (TVV) sequence.

Cell Line Retrovirus Clonogenic Efficiency (Relative to C127 Cells) Inhibition of Clonogenic Proliferation (Relative to ErbB4 Q646C K751M)
DU-145(n=5) ErbB4 Q646C K751M 4.6% N/A
ErbB4 Q646C EGFP 5.5% None
ErbB4 Q646C EGFP-TVV 0.8% 82 ± 2%
ErbB4 Q646C K751M EGFP-TVV 12.8% None
ErbB4 Q646C V673I EGFP-TVV 5.2% None
ErbB4 Q646C LL783/4AA EGFP-TVV 8.9% None
ErbB4 Q646C LL867/8AA EGFP-TVV 0.4% 92 ± 2%
ErbB4 Q646C L985A EGFP-TVV 2.8% 35 ± 10%
ErbB4 Q646C D990A EGFP-TVV 1.4% 69 ± 4%
ErbB4 Q646C Y1056F EGFP-TVV 9.7% None
PC-3(n=5) ErbB4 Q646C K751M 15.7% N/A
ErbB4 Q646C EGFP 24.9% None
ErbB4 Q646C EGFP-TVV 2.0% 89 ± 3%
ErbB4 Q646C K751M EGFP-TVV 22.9% None
ErbB4 Q646C V673I EGFP-TVV 8.9% 28 ± 17%
ErbB4 Q646C LL783/4AA EGFP-TVV 26.1% None
ErbB4 Q646C LL867/8AA EGFP-TVV 3.8% 80 ± 3%
ErbB4 Q646C L985A EGFP-TVV 8.5% 49 ± 6%
ErbB4 Q646C D990A EGFP-TVV 3.3% 78 ± 3%
ErbB4 Q646C Y1056F EGFP-TVV 23.4% None

Table 4: The K751M, V673I, LL783/4AA, and Y1056F mutations markedly disrupt the tumor suppressor activity of the constitutively-active ErbB4 Q646C EGFP-TVV construct in the DU-145 and PC-3 human prostate tumor cell lines.

Figure 1: ErbB4 Possesses Multiple Functional Motifs and Mutations Have Been Engineered to Target These Motifs. The organization of ErbB4 is as indicated in this schematic. The extracellular ligand-binding motifs reside in the amino-terminal region upstream of amino acid residue 651. The singlepass transmembrane domain consists of amino acid residues 652-675. The cytoplasmic tyrosine kinase domain consists of amino acid residues 713-989. The majority of cytoplasmic sites of tyrosine phosphorylation reside in amino acid residues 990-1308, most notably Tyr1056. Additional putative functional motifs include a TACE cleavage site, a gamma-secretase cleavage site, two LXXLL (steroid hormone receptor binding) motifs, a BH3 domain, three WW domain binding motifs, and a PDZ domain binding motif. Mutations that disrupt these motifs are noted. Finally, note the two locations of alternative transcriptional splicing, resulting in a total of four different splicing isoforms.

Figure 2: K751M, V673I, LL783/4AA, and L985A mutations profoundly disrupt the tumor suppressor activity of the constitutively-activeErbB4 Q646C construct in MCF7 and MCF10A cell lines. (a,b) MCF7 cells were infected with recombinant retroviruses based on the pLXSN vector as indicated. Infected cells were selected using G418 and colonies of infected, drug-resistant cells were stained using Giemsa and photographed. Images are representative of four independent experiments. The number of colonies was counted and the effects of the various constructs on clonogenic proliferation of MCF7 cells were analyzed as indicated elsewhere and reported in Table 1. (c) MCF10A cells were infected with recombinant retroviruses based on the pLXSN vector as indicated. Infected cells were selected using G418 and colonies of infected, drug-resistant cells were stained using Giemsa and photographed. Images are representative of at least three independent experiments. The number of colonies was counted and the effects of the various constructs on clonogenic proliferation of MCF10A cells were analyzed as indicated elsewhere and reported in Table 2.

Figure 3: The V673I, LL783/4AA, and L985A mutations do not markedly alter the expression or tyrosine phosphorylation of the constitutively-active ErbB4 Q646C construct. The expression and tyrosine phosphorylation of ErbB4 mutants expressed in ψ2 cell lines generated in the course of the experiments described in Figure 2 were analyzed by ErbB4 immunoprecipitation of ψ2 cell lysates and ErbB4 or anti-phosphotyrosine immunoblotting as described previously [40, 41]. These experiments were performed using 1 mg of lysate unless otherwise noted (100% indicates that 1 mg of lysate was used, 50% indicates that 0.5 mg of lysate was used, 25% indicates that 0.25 mg of lysate was used, and so on). Images are representative of three independent experiments.

Figure 4: An Enhanced Green Fluorescent Protein (EGFP) tag and the amino acid sequence Thr-Val-Val (TVV) have been added to the carboxyl terminus of the ErbB4 Q646C mutant. Standard subcloning techniques were used to move the EGFP sequence from the ErbB4-EGFP construct [10] to the ErbB4 Q646C construct [41], thereby generating the ErbB4 Q646C EGFP construct. Standard site-directed mutagenesis techniques were used to add the Thr-Val- Val (TVV) sequence to the extreme carboxyl terminus of the ErbB4 Q646C EGFP construct, thereby generating the ErbB4 Q646C EGFP-TVV construct.

Figure 5: Adding a carboxyl-terminal Enhanced Green Fluorescent Protein (EGFP) tag to the constitutively-active ErbB4 Q646C mutant disrupts its tumor suppressor activity, but this deficit is rescued by adding a carboxyl-terminal Thr-Val-Val (TVV) sequence. (a) PC-3 cells were infected with recombinant retroviruses based on the pLXSN-ErbB4 vector as indicated. Infected cells were selected using G418 and colonies of infected, drug-resistant cells were stained using Giemsa and photographed. Images are representative of three independent experiments. The number of colonies was counted and the effects of the various constructs on clonogenic proliferation of PC-3 cells were analyzed as indicated elsewhere and reported in Table 3. (b) DU-145 cells were infected with recombinant retroviruses based on the pLXSN vector as indicated. Infected cells were selected using G418 and colonies of infected, drug-resistant cells were stained using Giemsa and photographed. Images are representative of four independent experiments. The colonies were counted and the effects of the various constructs on clonogenic proliferation of DU- 145 cells were analyzed as indicated elsewhere and reported in Table 3.

Figure 6: The K751M, V673I, LL783/4AA, and Y1056F mutations markedly disrupt the tumor suppressor activity of the constitutively-active ErbB4 Q646C EGFP-TVV construct in thePC-3 human prostate tumor cell line. PC-3 cells were infected with recombinant retroviruses based on the pLXSN-ErbB4 vector as indicated. Infected cells were selected using G418 and colonies of infected, drug-resistant cells were stained using Giemsa and photographed. Images are representative of five independent experiments. The number of colonies was counted and the effects of the various constructs on clonogenic proliferation of PC-3 cells were analyzed as indicated elsewhere and reported in Table 4.

Figure 7: The K751M, V673I, LL783/4AA, and Y1056F mutations markedly disrupt the tumor suppressor activity of the constitutively-active ErbB4 Q646C EGFP-TVV construct in the DU-145 human prostate tumor cell line. DU-145 cells were infected with recombinant retroviruses based on the pLXSN vector as indicated. Infected cells were selected using G418 and colonies of infected, drug-resistant cells were stained using Giemsa and photographed. Images are representative of five independent experiments. The colonies were counted and the effects of the various constructs on clonogenic proliferation of DU- 145 cells were analyzed as indicated elsewhere and reported in Table 4.

Figure 8: The K751M, V673I, and Y1056F mutations disrupt the subcellular localization of the ErbB4 Q646C EGFP-TVV construct. The various ErbB4 Q646C EGFP-TVV constructs were transiently transfected into the PC-3 human prostate tumor cell line, after which the cells were stained with Hoescht 33342 (for DNA - blue) or MitoTracker Red CMXRos (for mitochondria - red). Cells were imaged by laser scanning confocal microscopy; the EGFPtagged proteins appear as green in these images. We photographed multiple randomly-selected, EGFP-positive cells per transfected plasmid per experiment. Images are representative of at least three independent experiments.